Targeting TGF-β signaling in cancer

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 7, 2013, Pages 743-760

  Katz, Lior H ^a   Li, Ying ^a   Chen, Jiun Sheng ^a   Muñoz, Nina M ^a   Majumdar, Avijit ^a   Chen, Jian ^a   Mishra, Lopa ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; TGF ; Tumor promotion; Tumor suppression

Indexed keywords

1D 11; 2 (5 CHLORO 2 FLUOROPHENYL) 4 (4 PYRIDINYLAMINO)PTERIDINE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; 4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; ANTINEOPLASTIC AGENT; AP 11014; AP 15012; CYCLIN DEPENDENT KINASE; DNA BINDING PROTEIN; FRESOLIMUMAB; GALUNISERTIB; GEMCITABINE; KI 26894; LERDELIMIMAB; LERDELIMUMAB; LOMUSTINE; LY 2109761; LY 364937; METELIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; NSC 74859D; P 1446A 05; PF 03446962; SB 505124; SEOCALCITOL; SMAD PROTEIN; SORAFENIB; TEMOZOLOMIDE; TRABEDERSEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL MIGRATION; CELL PROLIFERATION; CHEMORADIOTHERAPY; COLON CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPITHELIAL MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE CONTROL; GENOMIC INSTABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE EVASION; KIDNEY CARCINOMA; LIVER CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PROMOTER REGION; PROTEIN TARGETING; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; SKIN CANCER; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

ANIMALS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84879037098     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.782287     Document Type: Review

References (182)

1. Massague J. TGFbeta in cancer. Cell 2008; 134(2): 215-30
2. Mishra L, Derynck R, Mishra B. Transforming growth factor-beta signaling in stem cells and cancer. Science 2005; 310(5745): 68-71 (Pubitemid 41434534)
3. Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009; 19(1): 89-102
4. Meulmeester E, Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol 2011; 223(2): 205-18
5. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425(6958): 577-84 (Pubitemid 37280136)
6. Souchelnytskyi S, Moustakas A, Heldin CH. TGF-beta signaling from a three-dimensional perspective: insight into selection of partners. Trends Cell Biol 2002; 12(7): 304-7 (Pubitemid 35013468)
7. Katuri V, Tang Y, Li C, et al. Critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression. Oncogene 2006; 25(13): 1871-86
8. Childs CB, Proper JA, Tucker RF, Moses HL. Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci USA 1982; 79(17): 5312-16
9. Zu X, Zhang Q, Cao R, et al. Transforming growth factor-beta signaling in tumor initiation, progression and therapy in breast cancer: an update. Cell Tissue Res 2012; 347(1): 73-84
10. Mishra L, Shetty K, Tang Y, et al. The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005; 24(37): 5775-89 (Pubitemid 43086137)
11. Keski-Oja J, Koli K, von Melchner H. TGF-beta activation by traction? Trends Cell Biol 2004; 14(12): 657-9
12. Rifkin DB. Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol Chem 2005; 280(9): 7409-12 (Pubitemid 40349631)
13. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113(6): 685-700 (Pubitemid 36724933)
14. Todorovic-Rakovic N, Milovanovic J, Nikolic-Vukosavljevic D. TGF-beta and its coreceptors in cancerogenesis: an overview. Biomarkers Med 2011; 5(6): 855-63
15. Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993; 73(7): 1435-44 (Pubitemid 23201155)
16. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006; 107(12): 4589-96 (Pubitemid 43882602)
17. Wrana JL, Attisano L, Wieser R, et al. Mechanism of activation of the TGF-beta receptor. Nature 1994; 370(6488): 341-7 (Pubitemid 2110860)
18. Wrana JL, Tran H, Attisano L, et al. Two distinct transmembrane serine/threonine kinases from Drosophila melanogaster form an activin receptor complex. Mol Cell Biol 1994; 14(2): 944-50 (Pubitemid 24036544)
19. Groppe J, Hinck CS, Samavarchi-Tehrani P, et al. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell 2008; 29(2): 157-68 (Pubitemid 351172827)
20. Tang Y, Katuri V, Dillner A, et al. Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. Science 2003; 299(5606): 574-7 (Pubitemid 36135157)
21. Mishra L, Katuri V, Evans S. The role of PRAJA and ELF in TGF-beta signaling and gastric cancer. Cancer Biol Ther 2005; 4(7): 694-9
22. Mishra L, Marshall B. Adaptor proteins and ubiquinators in TGF-beta signaling. Cytokine Growth Factor Rev 2006; 17(1-2): 75-87 (Pubitemid 43117517)
23. Tang B, de Castro K, Barnes HE, et al. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res 1999; 59(19): 4834-42 (Pubitemid 29472885)
24. Attisano L, Wrana JL. Mads and Smads in TGF beta signalling. Curr Opin Cell Biol 1998; 10(2): 188-94 (Pubitemid 28174761)
25. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390(6659): 465-71 (Pubitemid 28013118)
26. Kretzschmar M, Massague J. SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev 1998; 8(1): 103-11 (Pubitemid 28122148)
27. Tang Y, Katuri V, Srinivasan R, et al. Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res 2005; 65(10): 4228-37 (Pubitemid 40775661)
28. Xu L. Regulation of Smad activities. Biochim Biophys Acta 2006; 1759(11-12): 503-13 (Pubitemid 46054233)
29. Liu F, Pouponnot C, Massague J. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev 1997; 11(23): 3157-67 (Pubitemid 27528056)
30. Macias-Silva M, Abdollah S, Hoodless PA, et al. MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996; 87(7): 1215-24 (Pubitemid 27010105)
31. Souchelnytskyi S, Tamaki K, Engstrom U, et al. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem 1997; 272(44): 28107-15 (Pubitemid 27473621)
32. Chen Y, Lebrun JJ, Vale W. Regulation of transforming growth factor beta-and activin-induced transcription by mammalian Mad proteins. Proc Natl Acad Sci USA 1996; 93(23): 12992-7 (Pubitemid 26382757)
33. Hoodless PA, Haerry T, Abdollah S, et al. MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell 1996; 85(4): 489-500 (Pubitemid 26157188)
34. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 1997; 389(6651): 618-22 (Pubitemid 27446181)
35. Nishihara A, Hanai JI, Okamoto N, et al. Role of p300, a transcriptional coactivator, in signalling of TGF-beta. Genes Cells 1998; 3(9): 613-23 (Pubitemid 28518310)
36. Zhang Y, Musci T, Derynck R. The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function. Curr Biol 1997; 7(4): 270-6 (Pubitemid 27176853)
37. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 2012; 8(7): 964-78
38. Zhang Y, Derynck R. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol 1999; 9(7): 274-9 (Pubitemid 29305517)
39. Lin X, Duan X, Liang YY, et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell 2006; 125(5): 915-28 (Pubitemid 43795197)
40. Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007; 1775(1): 21-62 (Pubitemid 44881193)
41. Monga SP, Tang Y, Candotti F, et al. Expansion of hepatic and hematopoietic stem cells utilizing mouse embryonic liver explants. Cell Transplant 2001; 10(1): 81-9 (Pubitemid 32247073)
42. Saha T, Vardhini D, Tang Y, et al. RING finger-dependent ubiquitination by PRAJA is dependent on TGF-beta and potentially defines the functional status of the tumor suppressor ELF. Oncogene 2006; 25(5): 693-705 (Pubitemid 43214696)
43. Inoue Y, Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci 2008; 99(11): 2107-12
44. Dong C, Li Z, Alvarez R Jr, et al. Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 2000; 5(1): 27-34 (Pubitemid 30105433)
45. Wrana JL. Crossing Smads. Sci STKE 2000; 2000(23): RE1
46. Tsukazaki T, Chiang TA, Davison AF, et al. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 1998; 95(6): 779-91 (Pubitemid 29014458)
47. Zhang Y, Chang C, Gehling DJ, et al. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci USA 2001; 98(3): 974-9 (Pubitemid 32121172)
48. Mishra L, Tully RE, Monga SP, et al. Praja1, a novel gene encoding a RING-H2 motif in mouse development. Oncogene 1997; 15(19): 2361-8 (Pubitemid 27496986)
49. Chen HB, Shen J, Ip YT, Xu L. Identification of phosphatases for Smad in the BMP/DPP pathway. Genes Dev 2006; 20(6): 648-53
50. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19(1): 128-39
51. Grady WM, Rajput A, Myeroff L, et al. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 1998; 58(14): 3101-4 (Pubitemid 28335093)
52. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006; 17(1-2): 41-58 (Pubitemid 43117515)
53. Akiyama Y, Iwanaga R, Saitoh K, et al. Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology 1997; 112(1): 33-9 (Pubitemid 27008983)
54. Grady WM, Myeroff LL, Swinler SE, et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 1999; 59(2): 320-4 (Pubitemid 29048861)
55. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268(5215): 1336-8
56. Takenoshita S, Tani M, Nagashima M, et al. Mutation analysis of coding sequences of the entire transforming growth factor beta type II receptor gene in sporadic human colon cancer using genomic DNA and intron primers. Oncogene 1997; 14(10): 1255-8 (Pubitemid 27141930)
57. Parsons R, Myeroff LL, Liu B, et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 1995; 55(23): 5548-50
58. Wang D, Kanuma T, Mizunuma H, et al. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. Cancer Res 2000; 60(16): 4507-12 (Pubitemid 32103632)
59. Goggins M, Shekher M, Turnacioglu K, et al. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998; 58(23): 5329-32 (Pubitemid 28551110)
60. Chen T, Yan W, Wells RG, et al. Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases. Int J Cancer 2001; 93(5): 653-61 (Pubitemid 32695112)
61. Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996; 86(4): 543-52 (Pubitemid 26299486)
62. Yakicier MC, Irmak MB, Romano A, et al. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999; 18(34): 4879-83 (Pubitemid 29423571)
63. Maliekal TT, Antony ML, Nair A, et al. Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene 2003; 22(31): 4889-97 (Pubitemid 36981278)
64. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271(5247): 350-3
65. Miyaki M, Iijima T, Konishi M, et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 1999; 18(20): 3098-103 (Pubitemid 29261230)
66. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29(2): 117-29 (Pubitemid 32952643)
67. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996; 56(11): 2527-30 (Pubitemid 26170688)
68. Nagatake M, Takagi Y, Osada H, et al. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 1996; 56(12): 2718-20 (Pubitemid 26175725)
69. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996; 13(3): 343-6 (Pubitemid 26230501)
70. Hahn SA, Bartsch D, Schroers A, et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 1998; 58(6): 1124-6 (Pubitemid 28183196)
71. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998; 280(5366): 1086-8 (Pubitemid 28234951)
72. Gomis RR, Alarcon C, He W, et al. A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci USA 2006; 103(34): 12747-52 (Pubitemid 44298632)
73. Pardali K, Kurisaki A, Moren A, et al. Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 2000; 275(38): 29244-56 (Pubitemid 32043793)
74. Seoane J, Le HV, Shen L, et al. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004; 117(2): 211-23 (Pubitemid 38496241)
75. Staller P, Peukert K, Kiermaier A, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001; 3(4): 392-9 (Pubitemid 32288447)
76. Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002; 419(6908): 729-34 (Pubitemid 35177959)
77. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003; 3(11): 807-21
78. Jang CW, Chen CH, Chen CC, et al. TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol 2002; 4(1): 51-8
79. Boulanger CA, Wagner KU, Smith GH. Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression. Oncogene 2005; 24(4): 552-60 (Pubitemid 40188560)
80. Glick AB, Weinberg WC, Wu IH, et al. Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res 1996; 56(16): 3645-50 (Pubitemid 26272005)
81. Kirshner J, Jobling MF, Pajares MJ, et al. Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res 2006; 66(22): 10861-9 (Pubitemid 44876983)
82. Bornstein S, White R, Malkoski S, et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest 2009; 119(11): 3408-19
83. Joseph H, Gorska AE, Sohn P, et al. Overexpression of a kinase-deficient transforming growth factor-beta type II receptor in mouse mammary stroma results in increased epithelial branching. Mol Biol Cell 1999; 10(4): 1221-34 (Pubitemid 29193742)
84. BhowmickNA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303(5659): 848-51 (Pubitemid 38174665)
85. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146
86. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108(4): 601-9 (Pubitemid 32777740)
87. Chen CR, Kang Y, Siegel PM, Massague J. E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 2002; 110(1): 19-32 (Pubitemid 34874603)
88. Latres E, Malumbres M, Sotillo R, et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 2000; 19(13): 3496-506 (Pubitemid 30428227)
89. Chen CR, Kang Y, Massague J. Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA 2001; 98(3): 992-9 (Pubitemid 32121175)
90. Gomis RR, Alarcon C, Nadal C, et al. C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 2006; 10(3): 203-14 (Pubitemid 44311064)
91. Jen J, Harper JW, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994; 54(24): 6353-8
92. Padua D, Zhang XH, Wang Q, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008; 133(1): 66-77 (Pubitemid 351442989)
93. DeCoteau JF, Knaus PI, Yankelev H, et al. Loss of functional cell surface transforming growth factor beta (TGFbeta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997; 94(11): 5877-81
94. Rooke HM, Vitas MR, Crosier PS, Crosier KE. The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression. Leukemia 1999; 13(4): 535-41 (Pubitemid 29195281)
95. Capocasale RJ, Lamb RJ, Vonderheid EC, et al. Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sezary patients. Proc Natl Acad Sci USA 1995; 92(12): 5501-5
96. Fernandez T, Amoroso S, Sharpe S, et al. Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. J Exp Med 2002; 195(10): 1247-55 (Pubitemid 34564327)
97. Mori N, Morishita M, Tsukazaki T, et al. Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor beta signaling through interaction with CREB-binding protein/p300. Blood 2001; 97(7): 2137-44 (Pubitemid 32239097)
98. Kurokawa M, Mitani K, Irie K, et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998; 394(6688): 92-6 (Pubitemid 28321809)
99. Jakubowiak A, Pouponnot C, Berguido F, et al. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem 2000; 275(51): 40282-7 (Pubitemid 32064660)
100. Inman GJ. Switching TGFbeta from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 2011; 21(1): 93-9
101. Adorno M, Cordenonsi M, Montagner M, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137(1): 87-98
102. Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol 2007; 9(9): 1000-4 (Pubitemid 47338137)
103. Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002; 12(1): 22-9 (Pubitemid 34094985)
104. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139(5): 871-90
105. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009; 19(2): 156-72
106. Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007; 98(10): 1512-20 (Pubitemid 47308444)
107. Valcourt U, Kowanetz M, Niimi H, et al. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 2005; 16(4): 1987-2002 (Pubitemid 40471965)
108. Cheng N, Chytil A, Shyr Y, et al. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res 2008; 6(10): 1521-33
109. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133(4): 704-15 (Pubitemid 351636299)
110. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001; 7(10): 1118-22 (Pubitemid 33010019)
111. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005; 8(5): 369-80 (Pubitemid 41579832)
112. Arteaga CL, Hurd SD, Winnier AR, et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Investig 1993; 92(6): 2569-76 (Pubitemid 24006519)
113. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004; 172(12): 7335-40 (Pubitemid 38747593)
114. Castriconi R, Cantoni C, Della Chiesa M, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003; 100(7): 4120-5 (Pubitemid 36418167)
115. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10(8): 554-67
116. Hagedorn HG, Bachmeier BE, Nerlich AG. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (Review). Int J Oncol 2001; 18(4): 669-81
117. Porsch H, Bernert B, Mehic M, et al. Efficient TGFb-induced epithelialmesenchymal transition depends on hyaluronan synthase HAS2. Oncogene 2012; doi: 10.1038/onc.2012.475. [Epub ahead of print]
118. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3(6): 537-49 (Pubitemid 36808649)
119. Sanchez-Elsner T, Botella LM, Velasco B, et al. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001; 276(42): 38527-35
120. Larsson J, Goumans MJ, Sjostrand LJ, et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J 2001; 20(7): 1663-73 (Pubitemid 32299403)
121. Oshima M, Oshima H, Taketo MM. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 1996; 179(1): 297-302 (Pubitemid 26363265)
122. Stearns ME, Garcia FU, Fudge K, et al. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 1999; 5(3): 711-20 (Pubitemid 29131984)
123. Buck MB, Fritz P, Dippon J, et al. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res 2004; 10(2): 491-8 (Pubitemid 38173987)
124. Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993; 143(2): 381-9 (Pubitemid 24058193)
125. Biswas S, Guix M, Rinehart C, et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007; 117(5): 1305-13 (Pubitemid 46718418)
126. Giampieri S, Manning C, Hooper S, et al. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009; 11(11): 1287-96
127. Siegel PM, Shu W, Cardiff RD, et al. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003; 100(14): 8430-5 (Pubitemid 36842562)
128. Forrester E, Chytil A, Bierie B, et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005; 65(6): 2296-302 (Pubitemid 40490139)
129. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007; 6(10): 2609-17 (Pubitemid 350058141)
130. Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2005; 102(39): 13909-14 (Pubitemid 41377677)
131. Saito H, Tsujitani S, Oka S, et al. An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 2000; 20(6B): 4489-93 (Pubitemid 32141808)
132. Tsai JF, Jeng JE, Chuang LY, et al. Elevated urinary transforming growth factor-beta1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer 1997; 76(2): 244-50 (Pubitemid 27279666)
133. Papadopoulou E, Anagnostopoulos K, Tripsianis G, et al. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism. Neoplasma 2008; 55(3): 229-38
134. Saunier EF, Akhurst RJ. TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 2006; 6(7): 565-78 (Pubitemid 44691000)
135. Calone I, Souchelnytskyi S. Inhibition of TGFbeta signaling and its implications in anticancer treatments. Exp Oncol 2012; 34(1): 9-16
136. Hau P, Jachimczak P, Schlingensiepen R, et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007; 17(2): 201-12 (Pubitemid 47124417)
137. Schlingensiepen KH, Jaschinski F, Lang SA, et al. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci 2011; 102(6): 1193-200
138. Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, et al. TGF-beta signalling in colon carcinogenesis. Cancer Lett 2012; 314(1): 1-7
139. Oettle H, Seufferlein T, Luger T, et al. Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. J Clin Oncol 2012; 30. [abstract: 2012 ASCO meeting]
140. Nam JS, Terabe M, Mamura M, et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008; 68(10): 3835-43
141. Ganapathy V, Ge R, Grazioli A, et al. Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 2010; 9: 122
142. Morris JC, Shapiro GI, Tan AR, et al. A human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody (mAB) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 2008; 26: 9028
143. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002; 109(12): 1607-15 (Pubitemid 34663523)
144. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002; 109(12): 1551-9 (Pubitemid 34663517)
145. Rowland-Goldsmith MA, Maruyama H, Matsuda K, et al. Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 2002; 1(3): 161-7
146. Bandyopadhyay A, Zhu Y, Malik SN, et al. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 2002; 21(22): 3541-51 (Pubitemid 34587686)
147. van Meeteren LA, Thorikay M, Bergqvist S, et al. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem 2012; 287(22): 18551-61
148. Goff LW, De Braud FG, Cohen RB, et al. Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFbeta receptor involved in tumor angiogenesis. J Clin Oncol 2012; 30: e13606
149. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther 2004; 3(6): 737-45 (Pubitemid 39193755)
150. Matsuyama S, Iwadate M, Kondo M, et al. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res 2003; 63(22): 7791-8 (Pubitemid 37466711)
151. Tanaka H, Shinto O, Yashiro M, et al. Transforming growth factor beta signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol Rep 2010; 24(6): 1637-43
152. Takeuchi K, Abe M, Hiasa M, et al. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One 2010; 5(3): e9870
153. DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004; 65(3): 744-52 (Pubitemid 38264042)
154. Ehata S, Hanyu A, Fujime M, et al. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007; 98(1): 127-33 (Pubitemid 44803931)
155. Shinto O, Yashiro M, Kawajiri H, et al. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer 2010; 102(5): 844-51
156. Bandyopadhyay A, Agyin JK, Wang L, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 2006; 66(13): 6714-21 (Pubitemid 44085629)
157. Uhl M, Aulwurm S, Wischhusen J, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004; 64(21): 7954-61 (Pubitemid 39446929)
158. Mohammad KS, Javelaud D, Fournier PG, et al. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 2011; 71(1): 175-84
159. Melisi D, Ishiyama S, Sclabas GM, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008; 7(4): 829-40 (Pubitemid 351551036)
160. Korpal M, Yan J, Lu X, et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009; 15(8): 960-6
161. Zhang B, Halder SK, Zhang S, Datta PK. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett 2009; 277(1): 114-20
162. Connolly EC, Saunier EF, Quigley D, et al. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TbetaRI/II kinase inhibition with LY2109761. Cancer Res 2011; 71(6): 2339-49
163. Yakymovych I, Engstrom U, Grimsby S, et al. Inhibition of transforming growth factor-beta signaling by low molecular weight compounds interfering with ATPor substrate-binding sites of the TGF beta type I receptor kinase. Biochemistry 2002; 41(36): 11000-7 (Pubitemid 35001214)
164. Bueno L, de Alwis DP, Pitou C, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 2008; 44(1): 142-50 (Pubitemid 350256941)
165. Rodon Ahnert J, Baselga J, Calvo E, et al. First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. J Clin Oncol 2011; 29: abstract 3011
166. Zhao BM, Hoffmann FM. Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol Biol Cell 2006; 17(9): 3819-31 (Pubitemid 44330868)
167. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006; 5(12): 997-1014 (Pubitemid 44835127)
168. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009; 18(1): 45-56
169. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol 2001; 19(3): 114-20 (Pubitemid 32155432)
170. Gupta S, Jain MM, Maru A, et al. A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors. J Clin 2012; 30: abstract 3011
171. Shah S, Islam MN, Dakshanamurthy S, et al. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell 2006; 21(6): 799-809 (Pubitemid 43376130)
172. LarribaMJ, Valle N, Palmer HG, et al. The inhibition ofWnt/beta-catenin signalling by 1alpha, 25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells. Endocr Relat Cancer 2007; 14(1): 141-51 (Pubitemid 47521730)
173. Walia B, Wang L, Merlin D, Sitaraman SV. TGF-beta down-regulates IL-6 signaling in intestinal epithelial cells: critical role of SMAD-2. Faseb J 2003; 17(14): 2130-2
174. Tang Y, Kitisin K, Jogunoori W, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA 2008; 105(7): 2445-50 (Pubitemid 351520533)
175. Lin L, Amin R, Gallicano GI, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 2009; 28(7): 961-72
176. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965; 122(3): 467-81
177. Thomas P, Forse RA, Bajenova O. Carcinoembryonic antigen (CEA) and its receptor hnRNP M are mediators of metastasis and the inflammatory response in the liver. Clin Exp Metastasis 2011; 28(8): 923-32
178. Bajenova OV, Zimmer R, Stolper E, et al. Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells. J Biol Chem 2001; 276(33): 31067-73
179. Li Y, Cao H, Jiao Z, et al. Carcinoembryonic antigen interacts with TGF-{beta} receptor and inhibits TGF-{beta} signaling in colorectal cancers. Cancer Res 2010; 70(20): 8159-68
180. Roberts AB, Lamb LC, Newton DL, et al. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci USA 1980; 77(6): 3494-8 (Pubitemid 10012261)
181. Moses HL, Branum EL, Proper JA, Robinson RA. Transforming growth factor production by chemically transformed cells. Cancer Res 1981; 41(7): 2842-8 (Pubitemid 11071822)
182. Deharvengt S, Marmarelis M, Korc M. Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer. PloS One 2012; 7(6): e39684